Syncell Inc. Company Profile

Background

Vision and Mission

Syncell Inc. is dedicated to accelerating research and translational discoveries to impact human health. The company's mission is to enable spatial protein purification for proteomic discovery, facilitating the identification of cell subtypes and states, novel protein drug targets at disease-associated locations, biomarkers for diseases, and mechanisms of biological pathways.

Company Overview

Founded in 2020 as a spin-off from Academia Sinica, Syncell is a life science technology company specializing in next-generation proteomics solutions. The company launched its first Microscoop® platform, Microscoop Mint, along with proprietary reagents Synlight™ and Synpull™, in 2024. These innovations address the need for high-precision microscopy-guided proteomic discovery, enabling researchers to perform spatial protein purification and proteomic discovery at visually recognizable regions of interest.

Milestones

• 2014: Initiated Microscoop® design.

• 2015: Began Microscoop® prototyping at Academia Sinica.

• 2017: Filed foundational system and method intellectual property.

• 2020: Official incorporation of Syncell.

• 2022: Launched customer service program.

• 2024: Commercial launch of Microscoop®.

Key Strategic Focus

Syncell's strategic focus centers on providing unique solutions for next-generation proteomics that are unbiased, deep, spatially precise, highly sensitive, and highly specific. The company's core objectives include:

• Microscopy-Guided Spatial Protein Purification: Enabling proteomic discovery at any visually recognizable regions of interest.

• Technological Integration: Combining photochemistry, microscopy, artificial intelligence-driven image processing, mechatronics, and biochemistry into a streamlined and user-friendly system.

• Target Markets: Addressing the needs of biological researchers in fields such as oncology, neurodegenerative diseases, infectious diseases, metabolic diseases, and developmental biology.

Financials and Funding

Funding History

• Series A Funding (2024): Raised $15 million, bringing total funding to $30 million. The round was led by Taiwania Capital, with participation from new and existing investors.

Utilization of Capital

The funds are intended to:

• Expand and accelerate the global commercialization and support for the Microscoop® platform.

• Build out a full commercial team and scale operations to meet growing demand.

• Establish new offices in the U.S. and Taiwan to support international expansion.

Pipeline Development

Microscoop® Platform

• Launch: Commercially launched in 2024.

• Applications: Enables high-precision, unbiased, spatial proteomic discovery in subcellular tissues or cells, allowing researchers to discover new protein components from targeted regions of interest.

• Target Conditions: Applicable to research in oncology, neurodegenerative diseases, infectious diseases, metabolic diseases, and developmental biology.

• Milestones: Placement of instruments in the U.S., Europe, and Asia by the end of 2024.

Technological Platform and Innovation

Proprietary Technologies

• Microscoop®: The world's first in-cell "pickable" microscope that applies an AI algorithm to selectively recover proteins and nucleic acids from specified subcellular locations.

Significant Scientific Methods

• Microscopy-Guided Photo-Biotinylation: Photolabeling proteins within user-defined regions of interest in cells or tissues, allowing precise extraction of proteins from fields of view with similar morphological features.

AI-Driven Capabilities

• Image Processing: Utilizing artificial intelligence-driven image processing to enhance the precision and efficiency of spatial proteomic discovery.

Leadership Team

• Jung-Chi Liao, PhD: Founder & CEO. Developed Microscoop® technology at Academia Sinica since 2014. Former faculty at Columbia University.

• Philippe Lyko: Chief Financial Officer. Former senior executive at Illumina and GE.

Advisors

• William Moerner, PhD: Nobel Laureate and scientific advisor.

• Martin Madaus: Business strategic advisor; founder of Millipore, acquired by Merck for $7.2 billion.

• Don Kania: Corporate advisor; former executive at FEI, acquired by Thermo Fisher for $4.2 billion.

Leadership Changes

• 2024: Appointment of Philippe Lyko as Chief Financial Officer.

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The spatial proteomics market is experiencing significant growth, driven by advancements in proteomic technologies and increasing demand for high-resolution spatial analysis in biomedical research.

• Industry Trends: There is a trend towards integrating artificial intelligence and machine learning with proteomic technologies to enhance data analysis and interpretation.

Competitor Analysis

• Key Competitors: Companies such as Dermavant Sciences, Metrum Research Group, and Clovis Oncology are operating in related biotech sectors.

• Primary Focus Areas: These competitors focus on various aspects of biotechnology, including drug development and research services.

• Technologies and Achievements: While these companies have made notable advancements in their respective fields, Syncell's unique combination of microscopy-guided photochemistry and AI-driven image processing sets it apart in the spatial proteomics landscape.

Strategic Collaborations and Partnerships

• Thermo Fisher Scientific: Signed a memorandum of understanding covering mass spectrometer instruments and workflows, supporting Syncell's growth across industry segments.

Operational Insights

Strategic Considerations

• Market Position: Syncell's innovative Microscoop® platform positions the company as a leader in the spatial proteomics field.

• Competitive Advantages: The integration of AI-driven image processing with microscopy-guided photochemistry provides a unique and powerful tool for researchers, differentiating Syncell from competitors.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Global Expansion: Establishing new offices in the U.S. and Taiwan to support international growth.

• Product Development: Continued enhancement of the Microscoop® platform to meet evolving research needs.

Opportunities for Expansion

• Collaborations: Building relationships with downstream technology partners to support growth across industry segments.

• Market Penetration: Expanding the customer base in the U.S., Europe, and Asia through strategic marketing and sales initiatives.

Positioning for Future Objectives

• Innovation: Maintaining a focus on technological innovation to stay ahead in the rapidly evolving field of spatial proteomics.

• Customer Success: Working closely with customers to maximize their success in discovering key protein players for specific research problems.

Contact Information

• Website: www.syncell.com

• LinkedIn: Syncell Inc.

• Headquarters: Taipei City, Taiwan

• U.S. Office: Watertown, Massachusetts, USA